Figure 4个  Table 2个
    • Mild/moderate cases Severe/critical cases P
      Total 56 (63.64%) 32 (36.36%)
      Gender 0.136
        Male 24 (42.86%) 19 (59.38%)
        Female 32 (57.14%) 13 (40.62%)
      Age (mean ± SD, years) 57.05 ± 13.94 55.34 ± 12.89 0.571
      Sample collecting time (days)a 0.003
        Median 12 9
        Interquartile range 9–18 5–12
      Nucleic acid test 0.748
        Positive 42 (75.00%) 23 (71.88%)
        Negative 14 (25.00%) 9 (28.13%)
      Antibody tests
        IgM positive 24 (42.86%) 5 (15.63%) 0.009
        IgM negative 32 (57.14%) 27 (84.37%)
        IgG positive 44 (78.57%) 14 (43.75%) 0.001
        IgG negative 12 (21.43%) 18 (56.25%)
      aSampling time: the time interval between symptom onset and sample collection

      Table 1.  Demographic information and test results of the studied subjects.

    • NAT resultsa Antibody test resultsa Total
      IgM IgG/IgM + IgG
      Positive Negative Positive Negative
      Positive 20 (22.73%) 45 (51.14%) 39 (44.32%) 26 (29.55%) 65 (73.86%)
      Negative 9 (16.98%) 14 (15.91%) 19 (21.59%) 4 (4.54%) 23 (26.14%)
      Total 29 (32.95%) 59 (67.05%) 58 (65.91%) 30 (34.09%) 88 (100%)
      aCombination of NAT and antibody test had significantly higher detection rate than single NAT (χ2 = 15.793, P < 0.001) or serologic test (χ2 = 24.643, P < 0.001).

      Table 2.  Comparison of results of serum SARS-CoV-2 antibody tests and nucleic acid test (NAT).